Abstract
Inflammation is a highly regulated process involved both in the response to pathogens as well as in tissue homeostasis. In recent years, a complex network of proteins in charge of inflammation control has been revealed by the study of hereditary periodic fever syndromes. Most of these proteins belong to a few families and share the capability of sensing pathogen-associated and damageassociated molecular patterns. By interacting with each other, these proteins participate in the assembly of molecular platforms, called inflammasomes, which ultimately lead to the activation of cytokines, to the transcription of inflammatory genes or to the induction of cell apoptosis. Among hereditary periodic fever syndromes, mevalonate kinase deficiency (MKD) is the sole in which the phenotype did not directly associate with a deficiency of these proteins, but with a metabolic defect of the mevalonate pathway, highlighting the importance of this metabolic pathway in the inflammation control. Noteworthy, drugs acting on this pathway can greatly influence the inflammatory response. The modulation of inflammation by mevalonate pathway is of interest, since it may involve mechanisms not directly referable to inflammasomes. MKD provides a model to study these mechanisms and possibly to develop new classes of anti-inflammatory drugs.
Keywords: Mevalonate, statin, aminobisphosphonate, inflammation, cholesterol
Current Pharmaceutical Design
Title:Mevalonate Kinase Deficiency: Disclosing the Role of Mevalonate Pathway Modulation in Inflammation
Volume: 18 Issue: 35
Author(s): Annalisa Marcuzzi, Sergio Crovella, Lorenzo Monasta, Liza Vecchi Brumatti, Marco Gattorno and Joost Frenkel
Affiliation:
Keywords: Mevalonate, statin, aminobisphosphonate, inflammation, cholesterol
Abstract: Inflammation is a highly regulated process involved both in the response to pathogens as well as in tissue homeostasis. In recent years, a complex network of proteins in charge of inflammation control has been revealed by the study of hereditary periodic fever syndromes. Most of these proteins belong to a few families and share the capability of sensing pathogen-associated and damageassociated molecular patterns. By interacting with each other, these proteins participate in the assembly of molecular platforms, called inflammasomes, which ultimately lead to the activation of cytokines, to the transcription of inflammatory genes or to the induction of cell apoptosis. Among hereditary periodic fever syndromes, mevalonate kinase deficiency (MKD) is the sole in which the phenotype did not directly associate with a deficiency of these proteins, but with a metabolic defect of the mevalonate pathway, highlighting the importance of this metabolic pathway in the inflammation control. Noteworthy, drugs acting on this pathway can greatly influence the inflammatory response. The modulation of inflammation by mevalonate pathway is of interest, since it may involve mechanisms not directly referable to inflammasomes. MKD provides a model to study these mechanisms and possibly to develop new classes of anti-inflammatory drugs.
Export Options
About this article
Cite this article as:
Marcuzzi Annalisa, Crovella Sergio, Monasta Lorenzo, Vecchi Brumatti Liza, Gattorno Marco and Frenkel Joost, Mevalonate Kinase Deficiency: Disclosing the Role of Mevalonate Pathway Modulation in Inflammation, Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530835
DOI https://dx.doi.org/10.2174/138161212803530835 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Serum Proteomics in the Diagnosis and Treatment of Haematological Malignancies
Current Proteomics Recent Developments in Targeting Breast Cancer Stem Cells
Recent Patents on Regenerative Medicine Cell Proliferation and Cytotoxicity Assays
Current Pharmaceutical Biotechnology The Application of Fungal Beta-glucans for the Treatment of Colon Cancer
Anti-Cancer Agents in Medicinal Chemistry Targeting Strategies in Therapeutic Applications of Toxoplasmosis: Recent Advances in Liposomal Vaccine Delivery Systems
Current Drug Targets Ellipticine, its Derivatives: Re-evaluation of Clinical Suitability with the Aid of Drug Delivery Systems
Current Cancer Drug Targets MicroRNAs and Cancer; an Overview
Current Pharmaceutical Biotechnology Treatment of Relapsed Acute Myeloid Leukaemia
Reviews on Recent Clinical Trials Topical Melatonin Niosome Gel for the Treatment of 5-FU-Induced Oral Mucositis in Mice
Current Drug Delivery Lymphatic Delivery of Anti-HIV Drug Nanoparticles
Recent Patents on Nanotechnology Bamboo a Supplement to Human Health: A Comprehensive Review on its Ethnopharmacology, Phytochemistry, and Pharmacological Activity
The Natural Products Journal Emerging Molecular Functions of MicroRNA-9: Cancer Pathology and Therapeutic Implications
Anti-Cancer Agents in Medicinal Chemistry Azoles as Effective Antifungal Agents: Trends, Scope and Relevance
The Natural Products Journal Histone Deacetylase Inhibitors: A New Wave of Molecular Targeted Anticancer Agents
Recent Patents on Anti-Cancer Drug Discovery In or Out Stemness: Comparing Growth Factor Signalling in Mouse Embryonic Stem Cells and Primordial Germ Cells
Current Stem Cell Research & Therapy Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
Current Cancer Therapy Reviews Inhibition of Hedgehog/Gli Signaling by Botanicals: A Review of Compounds with Potential Hedgehog Pathway Inhibitory Activities
Current Cancer Drug Targets Protein Phosphatase 1 and Its Complexes in Carcinogenesis
Current Cancer Drug Targets The Ubiquitin+Proteasome Protein Degradation Pathway as a Therapeutic Strategy in the Treatment of Solid Tumor Malignancies
Anti-Cancer Agents in Medicinal Chemistry Bench to Bedside Targeting of FLT3 in Acute Leukemia
Current Drug Targets